Michael Birrer, MD, PhD

Articles

PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian Cancer

September 4th 2020

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

Dr. Birrer on PARP Inhibitors in Ovarian Cancer

March 29th 2018

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer

June 20th 2017

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Dr. Birrer on Prevalence of Cervical Cancer in the United States

January 9th 2017

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the prevalence of cervical cancer in the United States.

Dr. Birrer on Challenges With Patient Demographics in Cervical Cancer

January 5th 2017

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the challenges associated with the patient demographics of cervical cancer.

Dr. Birrer on Patient Preferences for Cervical Cancer Treatment

December 29th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses patient preferences for cervical cancer treatment, as well as the demographics of this population.

Dr. Birrer on FDA Approval of Rucaparib in Ovarian Cancer

December 19th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the FDA approval of rucaparib for as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.

Dr. Birrer on the Need for Novel Treatment Options in Cervical Cancer

December 13th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the novel treatment options that could be explored in the future treatment of patients with cervical cancer.

Dr. Birrer on Remaining Challenges in Cervical Cancer

November 29th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the remaining challenges in treating patients with cervical cancer.

Dr. Michael Birrer on Immunotherapy Potential in Cervical Cancer

November 16th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses recent advancements in cervical cancer.

x